Zhou et al ,2001;Challen and Little,2006; Kenyon and Gerson, 2007; DeNicola et al, 2011; Nakasone et al, 2012; Rosenzweig, 2012
HI Khalid,
I do not understand your question, Are you asking if the low proliferation rate of CSC protect them from chemotherapy? if so, it is the idea, if a CSC (not sure that CSC exist, lets call them tumor initiating cells), or metastasic dormant cells do not proliferate, the drug will not attack them because in general chemotherapy (as DNA targeting drug Doxuribicin, or mitotic agents as paclitaxel) attack highly proliferative cells (definition of tumor cells = hyperproliferative cells). However, other therapies as hormone therapies can affect these low proliferative cells because the treatment is on a long period (up to 5 years for Estrogen analog tamoxifen, contrary to strong mitotic agent that act in few cycle of 1 day..)
Hope it is useful.
Read this paper to anderstund my question =D : http://www.nature.com/bjc/journal/v112/n11/full/bjc2015146a.html?WT.ec_id=BJC-201505
This paper is really difficult to understand. I am not a big fan of systems biology (I do not think as an engineer or mathematician). I believe in mutations and do think there is a huge genetic intratumoral heterogeneity that we cannot fully appreciate with the actual tools (single cell level or mutation it is hard).. sorry I cannot help.
- Badges
- Science topic
- Similar topics
- Medicine
- Oncology
- Cancer Research
- Cancer Biology
- Cancer Cells
- Cancer Stem Cells